-+ 0.00%
-+ 0.00%
-+ 0.00%

Allergy Therapeutics Plans Potential Equity Raise in 2026

MT Newswires·12/12/2025 04:22:04
Listen to the news
04:22 AM EST, 12/12/2025 (MT Newswires) -- Allergy Therapeutics (AGY.L) is considering a potential equity issue of up to 610 million new ordinary shares ahead of its planned dual listing on the Hong Kong Stock Exchange in the first half of 2026. As such, the British biotechnology company's board intends to seek shareholder approval for the transaction at the general meeting on Dec. 29, according to a Friday filing. Proceeds will be used to support drug development for grass and peanut allergies, as well as for general corporate purposes.